Ticker: DERM

Journey Medical Corporation (NASDAQ: DERM) - Snapshot from 10‑Q (period ended June 30, 2025) Quick take: Journey Medical's commercial-stage dermatology business shows revenue stability and an initial commercial ramp for newly approved Emrosi, but the company remains loss-making, carrying a sizabl...

Journey Medical Corporation (NASDAQ: DERM) has released its quarterly financial results for Q1 2025, which have brought both optimistic and challenging aspects to light. Positive Aspects: Revenue for Q1 2025 was $13.1 million, a slight increase from $13.0 million in Q1 2024, indicating stable sa...